Friday, January 20, 2012

Nektar high on development of new opioid

After the pain of its past, it’s fitting that Nektar Therapeutics Inc. looks to a new-style pain-killer as a salve.
The San Francisco drug developer, jarred four years ago by partner Pfizer Inc.’s sudden decision to kill Nektar’s lead product, expects to start a Phase II trial by the middle part of 2012 of the first new pain-fighting opioid in several years.

No comments:

Post a Comment